North of England evidence based guideline development project: Guideline on the use of aspirin as secondary prophylaxis for vascular disease in primary care

BMJ

Volumn 316, Issue 7140, 1998, Pages 1303-

  Eccles, Martin ^a   Freemantle, Nick ^a   Mason, James ^a  

^a The North of England Aspirin Guideline Development Group   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT;

ANGINA PECTORIS; COST EFFECTIVENESS ANALYSIS; EVIDENCE BASED MEDICINE; HEART INFARCTION; HUMAN; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; SECONDARY PREVENTION; STROKE; TRANSIENT ISCHEMIC ATTACK; UNITED KINGDOM; VASCULAR DISEASE;

ANGINA PECTORIS; ASPIRIN; CARDIOVASCULAR DISEASES; CEREBROVASCULAR DISORDERS; CONSUMER PRODUCT SAFETY; COST-BENEFIT ANALYSIS; DIABETES MELLITUS; DRUG ADMINISTRATION SCHEDULE; DRUG COSTS; HUMANS; INTERMITTENT CLAUDICATION; ISCHEMIC ATTACK, TRANSIENT; MYOCARDIAL INFARCTION; PLATELET AGGREGATION INHIBITORS; PRACTICE GUIDELINES; VASCULAR DISEASES;

EID: 18244410677     PISSN: 09598138     EISSN: 14685833     Source Type: Journal    
DOI: 10.1136/bmj.316.7140.1303     Document Type: Article

References (124)

1. North of England Evidence Based Guidelines Development Project. Evidence based guideline for the use of aspirin for the secondary prophylaxis of vascular disease in primary care. Newcastle upon Tyne: Centre for Health Services Research, 1997.
2. McCormick A. Fleming D. Charlton J. Morbidity statistics from general practice. Fourth national study 1991-1992. London: HMSO, 1995.
3. Eccles M. Freemantle N. Mason J. Methods of developing guidelines for efficient drug use in primary care. BMJ 1998;316:1232-1235.
4. Antiplatelet Trialists' Collaboration. Collaborative overview of randomised trials of antiplatelet treatment. I. Prevention of death, myocardial infarction and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ 1994;308:81-106.
5. Juul-Möller S. Edvardsson N. Jahnmatz B. Rosen A. Sorensen S. Ömblus R for the Swedish Angina Pectoris Aspirin Trial Group. Double blind trial of aspirin in primary prevention of myocardial infarction in patients with stable chronic angina pectoris. Lancet 1992;340:1421-1425.
6. SALT Collaborative Group. Swedish aspirin low-dose trial (SALT) of 75 mg aspirin as secondary prophylaxis after cerebrovascular ischaemic events. Lancet 1991;338:1345-1349.
7. Wallentin LC for the Research Group on Instability in Coronary Artery Disease in Southeast Sweden. Aspirin (75 mg/day) after an episode of unstable coronary artery disease: long-term effects on the risk for myocardial infarction, occurrence of severe angina and the need for revascularization. J Am Coll Cardiol 1991;18:1587-1593.
8. Nyman I. Larsson H. Wallentin L for the Research Group on Instability in Coronary Artery Disease in Southeast Sweden (RISC). Prevention of serious cardiac events by low-dose aspirin in patients with silent myocardial ischaemia. Lancet 1992;340:497-501.
9. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Randomised trial of intravenous streptokinase, oral aspirin, both or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. Lancet 1988; 2: 349-360.
10. Rasmanis G. Vesterqvist O. Green K. Edhag O. Henriksson P. Effects of intermittent treatment with aspirin on thromboxane and prostacyclin formation in patients with acute myocardial infarction. Lancet 1988; 2: 245-247.
11. Bjerre Knudsen J. Kjøller E. Skagen K. Gormsen J. The effect of ticlopidine on platelet functions in acute myocardial infarction., A double blind controlled trial. Thromb Haemost 1985;53: 3326.
12. Funke Küpper A.J. Verheugt F.W.A. Jaarsma W. Roos J.P. Failure of sulphinpyrazone to prevent left ventricular thrombosis in patients with A.M. treated with oral anticoagulants Proceedings of the X world congress on cardiology, Washington, DC 1986:419. (Abstract 2414.)
13. Funke Küpper A.J. Verheugt F.W.A. Peels C.H. Galema T.W. Effect of low dose acetyl salicylic acid on the frequency and hematologic activity of left ventricular thrombus in anterior wall acute myocardial infarction. Am J Cardiol 1989;63:917-920.
14. Verheugt F.W.A. Funke Küpper A.J. Galema T.W. Roos J.P. Low dose aspirin after early thrombolysis in anterior wall acute myocardial infarction. Am J Cardiol 1988;61:904-906.
15. Verheugt F.W.A. van-der-Laarse A. Funke Küpper A.J. Sterkman L.G.W. Galema T.W. Roos J.P. Effects of early intervention with low-dose aspirin (100 mg) on infarct size, reinfarction and mortality in anterior wall acute myocardial infarction. Am J Cardiol 1990;66:267-270.
16. Gent A.K. Brook C.G. Foley T.H. Miller T.N. Dipyridamole: a controlled trial of its effect in acute myocardial infarction. BMJ 1968; 4: 366-368.
17. Jones E.W. A study of dazoxiben in the prevention of venous thrombosis after suspected myocardial infarction [dissertation]. Nottingham: University of Nottingham, 1985.
18. Brochier M.L. for the Flurbiprofen French Trial. Evaluation of flurbiprofen for prevention of reinfarction and re-occlusion after successful thrombolysis or angioplasty in acute myocardial infarction. Eur Heart J 1993;14:951-957.
19. ISIS Pilot Study Investigators. Randomized factorial trial of high-dose intravenous streptokinase, of oral aspirin and of intravenous heparin in acute myocardial infarction. Eur Heart J 1987;8:634-642.
20. Baigent C. Collins R. ISIS-2: 4 year mortality follow up of 17,187 patients after fibrinolytic and antiplatelet therapy in suspected acute myocardial infarction. Circulation 1993;88:1-291.
21. Gentile R. Lagana B. Calcagni S. Borgia M.C. Baratta L. Efficacy of platelet inhibiting agents in the prevention of reinfarction in smoker patients Proceedings of the X world congress on cardiology, Washington, DC 1986:302. (Abstract 1724)
22. Breddin K. Loew D. Lechner K. Uberla K.K. Walter E on behalf of the German-Austrian Myocardial Infarction (GAMIS) Study Group. The German-Austrian aspirin trial: a comparison of acetylsalicylic acid, placebo and phenprocoumon in secondary prevention of myocardial infarction. Circulation 1980;62 (suppl V): 63-72.
23. Anturane Reinfarction Italian Study (ARIS) Research Group. Sulphinpyrazone in post- myocardial infarction. Lancet 1982; 1: 237-242.
24. Elwood P.C. Cochrane A.L. Burr M.I. Sweetnam P.M. Williams G.H. Welsby E et al. A randomized controlled trial of acetylsalicylic acid in the secondary prevention of mortality from myocardial infarction. BMJ 1974; 1: 436-440.
25. Elwood P.C. Trial of acetylsalicylic acid in the secondary prevention of mortality from myocardial infarction. BMJ 1981;282: 481.
26. Persantine-Aspirin Reinfarction Study (PARIS) Research Group. Persantine and aspirin in coronary heart disease. Circulation 1980;62:449-461.
27. Persantine-Aspirin Reinfarction Study (PARIS) Research Group. The persantine-aspirin reinfarction study. Circulation 1980;62 (suppl V):V85-V88.
28. Vogel G. Fischer C. Huyke R. Prevention of reinfarction with acetylsalicylic acid. In: Ed. Breddin H.K. Loew D. Uberla K. Dorndoff W. Marx R, eds. Prophylaxis of venous peripheral cardiac and cerebral vascular diseases with acetylsalicylic acid. Stuttgart: Shattauer, 1981:123-128.
29. Vogel G. Fischer C, Huyke R. Reinfarktprophylaxe mit Acetylsalizylsäure. Folia Haematol (Leipz) 1979;106:797-803.
30. Coronary Drug Project (CDP) Research Group. Aspirin in coronary heart disease. J Chronic Dis 1976;29:625-642.
31. Coronary Drug Project (CDP) Research Group. Aspirin in coronary heart disease. Circulation 1980;62 (suppl V): 59-62.
32. Coronary Drug Project (CDP) Research Group. The coronary drug project: design, methods and baseline results. Circulation 1973;47 (suppl 1): 149.
33. Anturane Reinfarction Trial (ART) Research Group. Sulfinpyrazone in the prevention of sudden death after myocardial infarction. N Engl J Med 1980;302:250-256.
34. Anturane Reinfarction Trial (ART) Research Group. The anturane reinfarction trial: re-evaluation of outcome. N Engl J Med 1982;306:1005-1008.
35. Sherry S. The anturane reinfarction trial. Circulation 1980;62 (suppl V): 73-78.
36. Temple B.A. Pledger G.W. The FDA's critique of the anturane reinfarction trial. N Engl J Med 1980;303:1488-1492.
37. Elwood P.C. Sweetnam P.M. Aspirin and secondary mortality after myocardial infarction. Lancet 1979; 2: 1313-1315.
38. Elwood P.C. Sweetnam P.M. Aspirin and secondary mortality after myocardial infarction. Circulation 1980;62 (suppl V): 53-58.
39. Klimt C.R. Knatterud G.L. Stamler J. Meier P. Persantine-aspirin reinfarction study. Part I.I. Secondary coronary prevention with persantine and aspirin. J Am Coll Cardiol 1986;7:251-269.
40. Aspirin Myocardial Infarction Study (AMIS) Research Group. AMIS: a randomized controlled trial of aspirin in persons recovered from myocardial infarction. JAMA 1980;243:661-669.
41. Becker M.C. Angina pectoris: a double blind study with dipyridamole. J Newark Beth Israel Hospital 1967;18:88-94.
42. Berglund U. Lassvik C. Wallentin I. Effects of the platelet inhibitor ticlopidine on exercise tolerance in stable angina pectoris. Eur Heart J 1987;8:25-30.
43. Berglund U. von Schenck H. Wallentin I. Effects of the platelet inhibitor ticlopidine on platelet function in men with stable angina pectoris. Thromb Haemost 1985;54:808-812.
44. Wirecki M. Treatment of angina pectoris with dipyridamole: a long-term double blind study. J Chronic Dis 1967;20:139-145.
45. Shar S. Schlant R.C. Dipyridamole in the treatment of angina pectoris. JAMA 1967;201:865-867.
46. Chesebro J.H. Webster M.W. Smith H.C. Frye R.I. Holmes D.R. Reeder GS et al. Antiplatelet therapy in coronary disease progression: reduced infarction and new lesion formation. Circulation 1989; 80 (suppl II): 266.
47. Lewis HD for the Veterans Administration Co-operative Study Group. Unstable angina: status of aspirin and other forms of therapy. Circulation 1985;72 (suppl V): 155-160.
48. ALDUSA (aspirin at low dose in unstable angina) pilot study. Report from the coordinating center. Lyon: Unite de Pharmacologie Clinique, 1987.
49. Aspirin Myocardial Infarction Study (AMIS) Research Group. AMIS: the aspirin myocardial infarction study: final results. Circulation 1980;62 (suppl V): 79-84.
50. Prandoni P. Milani L. Barbiero M. Cardaioli P. Sanson A. Barbaresi F et al. A combination of dipyridamole with low-dose aspirin in the treatment of unstable angina. Minerva Cardioangiol 1991; 39: 267-273.
51. Cairns J.A. Gent M. Singer J. Finnie K.J. Froggatt G.M. Holder DA et al. Aspirin, sulfinpyrazone, or both in unstable angina. Results of a Canadian multicentre trial. N Engl J Med 1985;313:1369-1375.
52. Balsano F. Rizzon P. Violi F. Scrutinio D. Cimmkiniello C. Aguglia F et al. for the Studio della Ticlopidina nell'Angina Instabile Group. Antiplatelet treatment with ticlopidine in unstable angina: a controlled multicentre clinical trial. Circulation 1990;82:17-26.
53. Scrutinio D. Lagioia R. Rizzon P on behalf of Studio della Ticlopidina nell'Angina Instabile Group. Ticlopidine treatment for patients with unstable angina at rest. A further analysis of the study of ticlopidine in unstable angina. Eur Heart J 1991; 12 (suppl G): 27-29.
54. Lewis H.D. Davis J.W. Archibald D.G. Steinke W.E. Smitherman T.C. Doherty J et al. Protective effects of aspirin against acute myocardial infarction and death in men with unstable angina. Results of a Veterans' Administration co-operative study. N Engl J Med 1983;309:396-403.
55. Ross Russell RW The effect of ticlopidine in patients with amaurosis fugax. Guildford: Sanofi Winthrop, 1985(Sanofi internal report 105062/0051.)
56. Gawel M. Rose F.C. Use of sulphinpyrazone in the prevention of restroke and stroke in man. In: Ed. Rose FC ed. Advances in stroke therapy. New York: Raven Press, 1982:158.
57. Reuther R. Dorndorf W. Loew D. Behandlung Transitorisch-ischamer Attacker mit Acetylsalicylsäure. Münchener Medizinische Wochenschrift 1980;122:795-798.
58. Reuther R. Dorndorf W. Aspirin in patients with cerebral ischaemia and normal angiograms or nonsurgical lesions. In: Breddin K. Dorndorf W. Loew D. Marx R, eds. Acetylsalicylic acid in cerebral ischaemia and coronary heart disease., Stuttgart: Schattauer, 1978:97-106.
59. Roden S. Low-Beer T. Carmalt M. Cockel R. Green I. Transient cerebral ischaemic attacks—management and prognosis. Postgrad Med J 1981;57:275-278.
60. Robertson J.T. Dugdale M. Salky N. Robinson H. The effect of a platelet inhibiting drug (sulfinpyrazone) in the therapy of patients with transient ischaemic attacks (TIAs) and minor strokes. Thrombosis et Diathesis Haemorrhagica 1975; 34: 598.
61. Acheson J. Danta G. Hutchinson E.C. Controlled trial of dipyridamole in cerebral vascular disease. BMJ 1969; 1: 614-615.
62. Acheson J. Danta G. Hutchinson E.C. Platelet adhesiveness in patients with cerebral vascular disease. Atherosclerosis 1972;15:123-127.
63. Sorensen P.S. Pedersen H. Marquardsen J. Petersson H. Heltberg A. Simonsen N et al. Acetylsalicylic acid in the prevention of stroke in patients with reversible cerebral ischaemic attacks. A Danish co-operative study. Stroke 1983;14:15-22.
64. Blakely J.A. A prospective trial of sulfinpyrazone and survival after thrombotic stroke. Proceedings of V.I. international congress on thrombosis and haemostasis, 1979:161. (Abstract 42.)
65. Boysen G. Soelberg-Sørensen P. Juhler M. Andersen A.R. Boas J. Olsen J.S. et al. Danish very-low-dose aspirin after carotid endarterectomy trial. Stroke 1988;19:1211-1215.
66. Fields W.S. Lemak N.A. Frankowski R.F. Hardy R.J. Controlled trial of aspirin in cerebral ischaemia. Stroke 1977;8:301-314.
67. Fields W.S. Lemak N.A. Frankowski R.F. Hardy R.J. Controlled trial of aspirin in cerebral ischaemia. Part I.I. Surgical group. Stroke 1978;9:309-318.
68. Lemak N.A. Fields W.S. Frankowski R.F. Hardy R.J. Controlled trial of aspirin in cerebral ischaemia: an addendum. Neurology 1986;36:705-710.
69. Guiraud-Chaumeil B. Rascol A. David J. Boneu B. Clanet M. Bierme R. Prevention des récidives des accidents vasculaires cérébraux ischemiques par les anti-agrégants plaquettaires. Rev Neurol (Paris) 1982;138:367-385.
70. Rascol A. Guiraud-Chaumeil B. Boneu B. David J. Clanet M. A long-term randomized trial of antiaggregating drugs in threatened stroke. In: Ed. Rose FC ed. Advances in stroke therapy. New York: Raven Press, 1982:147-153.
71. Canadian Co-operative Study Group. A randomized trial of aspirin and sulfinpyrazone in threatened stroke. N Engl J Med 1978;299:53-59.
72. Gent M. Barnett J.H.M. Sackett D.L. Taylor D.W. A randomized trial of aspirin and sulfinpyrazone in patients with threatened stroke. Results and methodologic issues. Circulation 1980; 62 (suppl V): 97-105.
73. Whisnant J.P. Matsumoto N. Elveback L.R. The Canadian trial of aspirin and sulphinpyrazone in threatened stroke. Am Heart J 1980;99:129-130.
74. Gent M. Blakely J.A. Hachinski V. Roberts R.S. Barnett H.J.M. Bayer N.H. et al. A secondary prevention randomized trial of suloctidil in patients with a recent history of thromboembolic stroke. Stroke 1985;16:416-424.
75. Britton M. Helmers C. Samuelsson K. High-dose acetylsalicylic acid after cerebral infarction—a Swedish co-operative study. Stroke 1987;18:325-334.
76. Bousser M.G. Eschwege E. Haguenau M. Lefauconnier J.M. Thibult N. Touboul D et al. AICLA controlled trial of aspirin and dipyridamole in the secondary prevention of athero- thrombotic cerebral ischaemia. Stroke 1983;14:5-14.
77. Bousser M.G. Eschwege E. Haguenau M. Lefauconnier J.M. Thibult N. Touboul D et al. Essai coopératif contrôlé de prévention secondaire des accidents ischémiques cérébraux liés à athérosclérose par l'aspirine et le dipyridamole. Presse Med 1983;12:3049-3057.
78. Gent M. Blakely J.A. Easton J.D. Ellis D.J. Hachinski V.C. Harbison JW et al. The Canadian American ticlopidine study (CATS) in thromboembolic stroke. Stroke 1988;19:1203-1210.
79. Gent M. Easton J.D. Hachinski V.C. Panak E. Sicurella J. Blakely JA et al. The Canadian American ticlopidine study (CATS) in thromboembolic stroke. Lancet 1989; 1: 1215-1220.
80. UK-TIA Study Group. United Kingdom transient ischaemic attack (UK-TM) aspirin trial: interim results. BMJ 1988;296:316-320.
81. UK-TIA Study Group. United Kingdom transient ischaemic attack (UK-TM) aspirin trial: final results. J Neurol Neurosurg Psychiatry 1991;54:1044-1054.
82. ESPS Group. The European stroke prevention study (ESPS). Principal endpoints. Lancet 1987; 2: 1351-1354.
83. ESPS Group. The European stroke prevention study (ESPS). Stroke 1990;21:122-130.
84. Bourde C. Eschwege E. Verry M. Controlled clinical trial of an antiaggregating agent, ticlopidine, in vascular ulcers of the leg. Thomb Haemost 1981;46: 91. (Abstract 0271.)
85. Bourde C. Giraud D. Correlations cliniques et téléthermographiques dans les ulcères de jambes d'origine vasculaire traités par un anti-aggrégant plaquettaire: la ticlopidine. J Mal Vasc 1982;4: 31 7.
86. Stuart J. Aukland A. Hurlow R.A. George A.J. Davies A.J. Ticlopidine in peripheral vascular disease. Proceedings of VI international congress of the Mediterranean League Against Thrombosism 1980:75-87. (Abstract 73.)
87. Adriansen H. Medical treatment of intermittent claudication: a comparative double-blind study of suloctidil, dihydroergotoxine, and placebo. Curr Med Res Opin 1976;4:395-401.
88. Shaw K. Assessment of the effect of ticlopidine on diabetic pre-gangrene. Guildford: Sanofi Winthrop, 1983(Sanofi internal report 001.6.241.)
89. Jones N.A.G. De Haas H. Zahavi J. Kakkar V.V. A double blind trial of suloctidil v placebo in intermittent claudication. Br J Surg 1982;69:38-40.
90. Krause D. Double blind study—ticlopidine versus placebo—in intermittent claudication. Guildford: Sanofi Winthrop, 1983(Sanofi internal report 001.6.170.)
91. Holm J. Lindblad L. Schersten T. Sunrkula M. Intermittent claudication: suloctidil vs placebo treatment. Vasa 1984;13:175-178.
92. Verhaeghe R. van Hoof A. Beyens G. Controlled trial of suloctidil in intermittent claudication. J Cardivasc Pharmacol 1981;3:279-286.
93. Signorini G.P. Salmistraro G. Maraglino G. Efficacy of indobufen in the treatment of intermittent claudication. Angiology 1988;39:742-745.
94. Aukland A. Hurlow R.A. George A.J. Stuart J. Platelet inhibition with ticlopidine in atherosclerotic intermittent claudication. J Clin Pathol 1982;35:740-743.
95. Hess H. Keil-Kuri E. Theoretische grundlagen der Prophylaxe Obliterinerender Arteriopathien mit Aggregationshemmern und Ergebnisse einer Langzeitstudie mit A.S. (Colfarit) Proceedings of the colfarit symposion III. Cologne, 1975:80-87.
96. Stiegler H. Hess H. Mietaschk A. Trampisch H.J. Ingrisch H. Einfluss von Ticlopidin auf die Periphere Obliterierende Arteriophie. Dtsch Med Wochenschr 1984;109:1240-1243.
97. Cloarec M. Caillard P. Mouren X. Double blind clinical trial of ticlopidine versus placebo in peripheral atherosclerotic disease of the legs. Thromb Res 1986;suppl VI:160.
98. Balsano F. Coccheri S. Libretti A. Nenci G.G. Catalano M. Fortunato G et al. Ticlopidine in the treatment of intermittent claudication: a 21-month double blind trial. J Lab Clin Med 1989;114:84-91.
99. Arcan J.C. Blanchard J. Boissel J.P. Destors J.M. Panak E. Multicentre double blind study of ticlopidine in the treatment of intermittent claudication and the prevention of its complications. Angiology 1988;39:802-811.
100. Destors J.M. Arcan J.C. Evaluation des médicaments par voie orale de la claudication intermittente des membres inférieurs à la phase I.I. des essais cliniques. Choix retenus dans l'étude ACT. Thérapie 1985;40:451-458.
101. Katsumura T. Mishima Y. Kamiya K. Sakaguchi S. Tanabe T. Sakuma A. Therapeutic effect of ticlopidine, a new inhibitor of platelet aggregation, on chronic arterial occlusive diseases, a double blind study versus placebo. Angiology 1982;33:357-367.
102. Ellis D.J. Treatment of intermittent claudication with ticlopidine. In: Proceedings of International Committee on Thrombosis and Haemostasis. 32nd Meeting, 1986:63:60. (Abstract addendum.)
103. Hess H. Mietaschk A. Deichsel G. Drug-induced inhibition of platelet function delays progression of peripheral occlusive arterial disease. A prospective double-blind arteriographically controlled trial. Lancet 1985; 1: 415-419.
104. Colwell J.A. Bingham S.F. Abraira C. Anderson J.W. Kwaan HC et al. for the Co-operative Study Group. VA co-operative study on antiplatelet agents in diabetic patients after amputation for gangrene: I. Design, methods and baseline characteristics. Controlled Clin Trials 1984;5:165-183.
105. Colwell J.A. Bingham S.F. Abraira C. Anderson J.W. Comstock J.P. Kwaan HC et al. Veterans Administration co-operative study on antiplatelet agents in diabetic patients after amputation for gangrene: I.I. Effects of aspirin and dipyridamole on atherosclerotic vascular disease rates. Diabetes Care 1986;9:140-148.
106. Schoop W. Levy H. Schoop B. Gaentzsch A. Experimentelle und Klinische Studien zu der sekundaren Prevention der Peripheren Arteriosklerose. In: Bollinger A. Rhyner K, eds. Thrombozytenfunktionshemmer, Wirkungsmechanismen, Dosierung und Praktische. Stuttgart: Thieme, 1983:49-58.
107. Schoop W. Levy H. Prevention of peripheral arterial occlusive disease with antiagreggants. Thromb Haemost 1983;50: 137.
108. Schoop W. Spatergebnisse bei Konservitiver Therapie der Arteriellen Verschlusskrankheit. Der Internist 1984;25:429-433.
109. Janzon L. Berqvist D. Boberg J. Boberg M. Eriksson I. Lindgarde F et al. Prevention of myocardial infarction and stroke in patients with intermittent claudication, effects of ticlopidine. Results from STIMS, the Swedish ticlopidine multicentre study. J Intern Med 1990;227:301-308.
110. Balsano F. Violi F. and ADEP Group. Effect of picotamide on the clinical progression of peripheral vascular disease. A double blind placebo controlled study. Circulation 1993;87:1563-1569.
111. Moher M. Lancaster T. Who needs antiplatelet therapy? Br J Gen Pract 1996;46:367-370.
112. Pollock A. Wright A.D. The effect of ticlopidine on platelet function in patients with diabetic peripheral arterial disease. Guildford: Sanofi Winthrop, 1979(Sanofi internal report 105062/0019.)
113. Nyberg G. Larsson O. Westberg N.G. Aurell M. Jagenburg R. Blohme G. A platelet aggregation inhibitor—ticlopidine—in diabetic nephropathy: a randomized double blind study. Clin Nephrol 1984;21:184-187.
114. Pannebakker M.A.U.I. Jonker J.J.C. Den Ottolander G.J.H. Influence of sulphinpyrazone on diabetic vascular complications. In: Proceedings of VI international congress of Mediterranean League Against Thrombosis. Monte Carlo, 1980. (Abstract 167.)
115. Oakley N.W. Dormandy J.A. Flute P.T. Investigation of the effect of ticlopidine in the incidence of cardiovascular events in selected high risk patients with diabetes. Guildford: Sanofi Winthrop, 1983(Sanofi internal report 105062/0019.)
116. Belgian Ticlopidine Retinopathy Study Group (BTRS). Clinical study of ticlopidine in diabetic retinopathy. Ophthalmologica 1992;204:4-12.
117. DAMAD Study Group. Effect of aspirin alone and aspirin plus dipyridamole in early diabetic retinopathy—a multi-centre randomized controlled clinical trial. Diabetes 1989;38:491-498.
118. Mirouze J on behalf of TIMAD Study Group. Ticlopidine in the secondary prevention of early diabetes-related microangiopathy: protocol of a multicentre therapeutic study (TIMAD study). Agents Actions 1984;15 (suppl): 230-258.
119. ETDRS Investigators. Aspirin effects on mortality and morbidity in patients with diabetes mellitus. Early treatment diabetic retinopathy study report 14. JAMA 1992;268:1292-1300.
120. ETDRS Research Group. Effects of aspirin treatment on diabetic retinopathy: ETDRS report number 8. Ophthalmology 1991;98 (suppl): 757-765.
121. Breddin K. Loew D. Lechner K. Uberla K.K. Walter E. Secondary prevention of myocardial infarction: a comparison of acetylsalicylic acid, placebo and phenprocoumon. Haemostasis 1980;9:325-344.
122. Uberla K. Multicentre two year prospective study on the prevention of secondary myocardial infarction by A.S. in comparison with phenprocoumon and placebo. In: Ed. Breddin K, ed. Acetylsalicylic acid in cerebral ischaemia and coronary heart disease. Stuttgart: Schattauer, 1978:159-169.
123. British National Formulary. No 32. London: British Medical Association and Royal Pharmaceutical Society of Great Britain, 1996.
124. Roderick P.J. Wilkes H.C. Meade T.W. The gastrointestinal toxicity of aspirin: an overview of randomised controlled trials. Br J Clin Pharmacol 1993;35:219-226.